These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 25556625)

  • 1. Eligibility and safety of the first interferon-free therapy against hepatitis C in a real-world setting.
    Höner Zu Siederdissen C; Maasoumy B; Deterding K; Port K; Sollik L; Mix C; Kirschner J; Cornberg J; Manns MP; Wedemeyer H; Cornberg M
    Liver Int; 2015 Jul; 35(7):1845-52. PubMed ID: 25556625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study.
    Dalgard O; Weiland O; Noraberg G; Karlsen L; Heggelund L; Färkkilâ M; Balslev U; Belard E; Øvrehus A; Skalshøi Kjær M; Krarup H; Thorup Røge B; Hallager S; Madsen LG; Lund Laursen A; Lagging M; Weis N
    PLoS One; 2017; 12(7):e0179764. PubMed ID: 28704381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of simeprevir plus sofosbuvir with or without ribavirin in patients with decompensated genotype 1 hepatitis C cirrhosis.
    Modi AA; Nazario H; Trotter JF; Gautam M; Weinstein J; Mantry P; Barnes M; Habib A; McAfee J; Teachenor O; Tujague L; Gonzalez S
    Liver Transpl; 2016 Mar; 22(3):281-6. PubMed ID: 26335142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simeprevir and sofosbuvir for treatment of chronic hepatitis C infection.
    Childs-Kean LM; Hand EO
    Clin Ther; 2015 Feb; 37(2):243-67. PubMed ID: 25601269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Limited effectiveness and safety profile of protease inhibitor-based triple therapy against chronic hepatitis C in a real-world cohort with a high proportion of advanced liver disease.
    Maasoumy B; Port K; Deterding K; Höner Zu Siederdissen C; Markova AA; Rogalska-Taranta M; Manns MP; Wedemeyer H; Cornberg M
    Eur J Gastroenterol Hepatol; 2014 Aug; 26(8):836-45. PubMed ID: 24987822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of sofosbuvir-based triple therapy in hepatitis C genotype 4 infection.
    Wehmeyer MH; Jordan S; Lüth S; Hartl J; Stoehr A; Eißing C; Lohse AW; Petersen J; Buggisch P; Schulze Zur Wiesch J
    Dig Liver Dis; 2015 Sep; 47(9):811-4. PubMed ID: 26091766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea.
    Cho Y; Cho EJ; Lee JH; Yu SJ; Yoon JH; Kim YJ
    Clin Mol Hepatol; 2015 Dec; 21(4):358-64. PubMed ID: 26770924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study.
    Molina JM; Orkin C; Iser DM; Zamora FX; Nelson M; Stephan C; Massetto B; Gaggar A; Ni L; Svarovskaia E; Brainard D; Subramanian GM; McHutchison JG; Puoti M; Rockstroh JK;
    Lancet; 2015 Mar; 385(9973):1098-106. PubMed ID: 25659285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lactic acidosis in patients with hepatitis C virus cirrhosis and combined ribavirin/sofosbuvir treatment.
    Welker MW; Luhne S; Lange CM; Vermehren J; Farnik H; Herrmann E; Welzel T; Zeuzem S; Sarrazin C
    J Hepatol; 2016 Apr; 64(4):790-9. PubMed ID: 26658684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.
    Charlton M; Gane E; Manns MP; Brown RS; Curry MP; Kwo PY; Fontana RJ; Gilroy R; Teperman L; Muir AJ; McHutchison JG; Symonds WT; Brainard D; Kirby B; Dvory-Sobol H; Denning J; Arterburn S; Samuel D; Forns X; Terrault NA
    Gastroenterology; 2015 Jan; 148(1):108-17. PubMed ID: 25304641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sofosbuvir (GS-7977), a pan-genotype, direct-acting antiviral for hepatitis C virus infection.
    Rodríguez-Torres M
    Expert Rev Anti Infect Ther; 2013 Dec; 11(12):1269-79. PubMed ID: 24215243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sofosbuvir plus simeprevir for the treatment of genotype 1 chronic hepatitis C: a review of evidence.
    Gimeno-Ballester V; Simón MÁ; Trigo C; Mar J; San Miguel R
    Expert Rev Gastroenterol Hepatol; 2016 Nov; 10(11):1289-1303. PubMed ID: 27626505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COMMON GENOTYPES AND TREATMENT OUTCOMES OF HCV INFECTION AMONG ETHIOPIAN PATIENTS: A PROSPECTIVE STUDY.
    Kassa E; Bane A; Kefene H
    Ethiop Med J; 2016 Jan; 54(1):1-7. PubMed ID: 27191024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual sofosbuvir and ribavirin therapy for chronic hepatitis C infection.
    Tang L; Ward H; Kattakuzhy S; Wilson E; Kottilil S
    Expert Rev Gastroenterol Hepatol; 2016; 10(1):21-36. PubMed ID: 26558305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).
    Bourlière M; Bronowicki JP; de Ledinghen V; Hézode C; Zoulim F; Mathurin P; Tran A; Larrey DG; Ratziu V; Alric L; Hyland RH; Jiang D; Doehle B; Pang PS; Symonds WT; Subramanian GM; McHutchison JG; Marcellin P; Habersetzer F; Guyader D; Grangé JD; Loustaud-Ratti V; Serfaty L; Metivier S; Leroy V; Abergel A; Pol S
    Lancet Infect Dis; 2015 Apr; 15(4):397-404. PubMed ID: 25773757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C.
    D'Ambrosio R; Aghemo A; Colombo M
    Expert Opin Drug Saf; 2015 Mar; 14(3):473-84. PubMed ID: 25645644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C therapy: Looking toward interferon-sparing regimens.
    Au TH; Destache CJ; Vivekanandan R
    J Am Pharm Assoc (2003); 2015; 55(2):e72-84; quiz e85-6. PubMed ID: 25658389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current Status of Direct Acting Antiviral Agents against Hepatitis C Virus Infection in Pakistan.
    Khaliq S; Raza SM
    Medicina (Kaunas); 2018 Nov; 54(5):. PubMed ID: 30400604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies.
    Deterding K; Höner Zu Siederdissen C; Port K; Solbach P; Sollik L; Kirschner J; Mix C; Cornberg J; Worzala D; Mix H; Manns MP; Cornberg M; Wedemeyer H
    Aliment Pharmacol Ther; 2015 Oct; 42(7):889-901. PubMed ID: 26250762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world experience with interferon-free, direct acting antiviral therapies in Asian Americans with chronic hepatitis C and advanced liver disease.
    Chang CY; Nguyen P; Le A; Zhao C; Ahmed A; Daugherty T; Garcia G; Lutchman G; Kumari R; Nguyen MH
    Medicine (Baltimore); 2017 Feb; 96(6):e6128. PubMed ID: 28178174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.